Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02128646 · ClinicalTrials.gov registry record · Phase 4

Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair

A Phase 4 study of Pain, sponsored by University of Kansas Medical Center.

Completed
Registry status
Phase 4
Development phase
19
Enrollment target
1
Study location

NCT02128646: Completed Phase 4 study of Pain, sponsored by University of Kansas Medical Center.

NCT02128646 is a Phase 4 study of Pain that has completed, run by University of Kansas Medical Center. The registered enrollment target is 19 participants, below the 304-participant average among 374 other Pain trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02128646, a Phase 4 study of Pain, has completed, sponsored by University of Kansas Medical Center.

COMPLETED
Registry status
Phase 4
Development phase
19 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

Primary Outcome

Satisfaction measured with composite score that includes score from the Likert scale and opioid consumption/satisfaction log. Satisfaction was rated on a scale of 1-5, with 1 being "strongly disagree"/not satisfied with pain control and 5 being "strongly agree"/satisfied with pain control. Patients filled out the log on days 1-4 after surgery and at a 7-14 day follow up visit.

Conditions Studied

Interventions

  • DRUG Ketorolac
  • DRUG EXPAREL
  • PROCEDURE laparoscopic abdominal hernia repair
  • PROCEDURE an open surgery for abdominal hernia repair

Study Locations (1)

Kansas

  • University of Kansas Medical Center - Kansas City

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2014-04
Est. Completion 2017-01
Phase Phase 4
University of Kansas Medical Center

408 total trials

What the finished NCT02128646 record still lists

NCT02128646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 19 participants, a relatively small participant target, below the 304-participant average among 374 other Pain trials with a reported enrollment target (94% lower).

The record links to 1 condition, with Pain appearing as the primary indexed condition, and to 4 interventions - of which Ketorolac is the first listed.

NCT02128646 reports a single indexed study location in Kansas.

Frequently Asked Questions

What is clinical trial NCT02128646 about?

NCT02128646 is a clinical study titled "Liposomal Bupivacaine (Exparel) for Postoperative Pain Control for Open and Laparoscopic Abdominal Hernia Repair". The purpose of this study is to learn how well Liposomal Bupivacaine (Exparel™) controls post-operative pain in patients undergoing both open and laparoscopic (minimally invasive) abdominal hernia repair surgery.

What is the current status of trial NCT02128646?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 19 participants. The study started on 2014-04. Estimated completion is 2017-01.

What conditions does trial NCT02128646 study?

This clinical trial studies the following conditions: Pain.

What interventions are being tested in trial NCT02128646?

The interventions under investigation include: Ketorolac (DRUG), EXPAREL (DRUG), laparoscopic abdominal hernia repair (PROCEDURE), an open surgery for abdominal hernia repair (PROCEDURE).

Who is sponsoring clinical trial NCT02128646?

This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02128646 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Pain

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02128646's enrollment target sits among peer trials

19 347th of 374 higher than 26 of 374 other Pain trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Pain trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03207464 · 19 participants · Phase 1

    Molecular Imaging of NET Using [C-11]MRB-PET in MS

  • NCT04318717 · 19 participants · Phase 2

    Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma

  • NCT05103904 · 19 participants · Phase 2

    Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

  • NCT05607407 · 19 participants · Phase 2

    Methimazole in Patients With Progressive Glioblastoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02128646, the US trial registry maintained by the National Library of Medicine. NCT02128646 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.